In accordance with the ELN 2022 guidelines, persistent detectable MRD in RUNX1::RUNX1T1-positive AML generally necessitates treatment escalation and consideration of allo-HSCT in eligible patients (1). The gene discussed is RUNX1; the disease is acute myeloid leukemia.